Pieris Pharmaceuticals In... (PIRS)
13.60
-2.51 (-15.58%)
At close: Dec 13, 2024, 9:00 PM
No 1D chart data available
| Bid | 9.05 |
| Market Cap | 17.96M |
| Revenue (ttm) | 1.35M |
| Net Income (ttm) | -15.96M |
| EPS (ttm) | -12.11 |
| PE Ratio (ttm) | -1.12 |
| Forward PE | -80.6 |
| Analyst | n/a |
| Ask | 15 |
| Volume | 51,728 |
| Avg. Volume (20D) | 22,969 |
| Open | 15.04 |
| Previous Close | 16.11 |
| Day's Range | 13.26 - 15.35 |
| 52-Week Range | 6.20 - 22.32 |
| Beta | 0.66 |
About PIRS
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate ...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 2, 2015
Employees 46
Stock Exchange NASDAQ
Ticker Symbol PIRS
Website https://www.pieris.com
7 months ago
+88.6%
Pieris Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
